Novartis announced on Thursday that the FDA has approved a label update for secukinumab (Cosentyx) to include moderate to severe scalp psoriasis, a particularly challenging form of psoriasis to treat, and a condition that affects approximately half of patients with psoriasis.
Novartis announced on Thursday that the FDA has approved a label update for secukinumab (Cosentyx) to include moderate to severe scalp psoriasis, a particularly challenging form of psoriasis to treat, and a condition that Novartis says affects approximately half of patients with psoriasis.
The label update was based on data from the phase 3 SCALP study of secukinumab versus placebo in 102 patients with scalp psoriasis. Patients were randomized to receive either 300 mg of secukinumab or placebo at weeks 0, 1, 2, and 3, and then every 4 weeks for 12 weeks. The proportion of patients who had an Investigator’s Global Assessment scalp-only score of 0 or 1 (clear or almost clear) during the study period were 56.9% for the secukinumab arm and 5.9% for the placebo arm.
Secukinumab was the first interleukin-17A inhibitor FDA-approved to treat moderate to severe plaque psoriasis, and the label update, says Eric Hughes, global development unit head of immunology and dermatology at Novartis, “…confirms the additional value Cosentyx offers to patients who seek a treatment effective in various areas of the body…we’re proud to expand treatment possibilities of Cosentyx for an even greater number of patients."
Already this year, Novartis released data from the head-to-head CLARITY study showing that secukinumab outperformed ustekinumab (Stelara) in treating psoriasis, and announced that it is initiating the SURPASS trial, a head-to-head clinical trial of secukinumab versus adalimumab in patients with ankylosing spondylitis. Already recruiting is the EXCEED trial, yet another head-to-head trial of secukinumab versus adalimumab in patients with psoriatic arthritis.
As the originator adalimumab (Humira) moves closer to patent expiry, secukinumab’s growing body of positive data may help it to compete for a substantial share of the inflammatory disease market against an increasing number of US- and EU-approved biosimilars. Already, secukinumab has become a top earner for Novartis, with 2017 sales of $615 million across all indications—up 53% from 2016—according to Novartis’ 2017 financial report.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.